Pliant Therapeutics, Inc. (PLRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant ...
NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
Pliant Therapeutics (PLRX) stock jumped 21% Thursday after the company issued an update for a Phase 2b clinical study of ...
Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Pliant Therapeutics in a report released on Monday, February 10th. HC Wainwright analyst E. Arce ...
Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have been given an average rating of “Hold” by the eleven analysts that are presently covering the company, Marketbeat reports.
Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.
Pliant Therapeutics, Inc. (NASDAQ:PLRX) stock is trading lower on Monday. On Friday, during after-hours trading, Pliant ...
Hosted on MSN4d
Citigroup Downgrades Pliant Therapeutics (PLRX)Fintel reports that on February 10, 2025, Citigroup downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Buy ...
Check the time stamp on this data. Updated AI-Generated Signals for Pliant Therapeutics Inc. (PLRX) available here: PLRX.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback